cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vaxart Inc
103 own
36 watching
Current Price
$0
$0
(0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
122.06M
52-Week High
52-Week High
4.615
52-Week Low
52-Week Low
0.56
Average Volume
Average Volume
3.5M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization122.06M
icon52-Week High4.615
icon52-Week Low0.56
iconAverage Volume3.5M
iconDividend Yield--
iconP/E Ratio--
What does the Vaxart Inc do?
Aviragen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections worldwide. Its product candidates include vapendavir, which is in Phase IIb SPIRITUS trial for an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA585, an oral fusion protein inhibitor, which is in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, an antiviral treatment that is in Phase II development for condyloma caused by human papillomavirus types 6 and 11. Aviragen Therapeutics, Inc. has collaboration agreement with Daiichi-Sankyo for the development of Laninamivir octanoate, a neuraminidase inhibitor, which has completed Phase II clinical trial for the treatment of influenza. The company was formerly known as Biota Pharmaceuticals, Inc. and changed its name to Aviragen Therapeutics, Inc. in April 2016. Aviragen Therapeutics, Inc. is based in Alpharetta, Georgia.
Read More
How much money does Vaxart Inc make?
News & Events about Vaxart Inc.
Globe Newswire
1month ago
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT)today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4, ...
Globe Newswire
2 months ago
Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host a key opinion leader video webcast on the health and ...
Globe Newswire
3 months ago
Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent norovirus ...
Globe Newswire
5 months ago
Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc.(NASDAQ: VXRT) announced today that it has appointed Phillip Lee as its Chief Financial Officer (CFO), ...
Globe Newswire
6 months ago
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ...
Frequently Asked Questions
Frequently Asked Questions
What is Vaxart Inc share price today?
plus_minus_icon
Can Indians buy Vaxart Inc shares?
plus_minus_icon
How can I buy Vaxart Inc shares from India?
plus_minus_icon
Can Fractional shares of Vaxart Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Vaxart Inc stocks?
plus_minus_icon
What is today’s traded volume of Vaxart Inc?
plus_minus_icon
What is today’s market capitalisation of Vaxart Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Vaxart Inc?
plus_minus_icon
What percentage is Vaxart Inc down from its 52-Week High?
plus_minus_icon
What percentage is Vaxart Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SOLID BIOSCIENCES INC
SOLID BIOSCIENCES INC
$6.35
$0.08 (1.28 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$2.31
$0.13 (5.73 %)
AVROBIO INC
AVROBIO INC
$1.22
$0.02 (1.25 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.95
$0.00 (0.04 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SOLID BIOSCIENCES INC
SOLID BIOSCIENCES INC
$6.35
$0.08 (1.28 %)
GAMIDA CELL LTD
GAMIDA CELL LTD
$2.31
$0.13 (5.73 %)
AVROBIO INC
AVROBIO INC
$1.22
$0.02 (1.25 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.95
$0.00 (0.04 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00